FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

pe Response	s)															
1. Name and Address of Reporting Person * Mann Brenda				2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title below) Other (specify below)				
(Last) (First) (Middle) C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLY OAKS ROAD, SUITE 108				3. Date of Earliest Transaction (Month/Day/Year) 01/03/2020									VP of Re	search & De	evelopment	
(Street) WALTHAM MA 02452				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person					
	(State)	(Zip)		Tab	ole I - N	lon-l	Deriva	ative S	ecuritio	es Ac	quir	ed, Dispo	sed of, or I	Beneficially	Owned	
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	any		f Code (Instr. 8)		(A) or Disposed of (Instr. 3, 4 and 5)		of (E	D) E	Beneficia Reported	lly Owned Following Transaction(s)		Ownership Form: Direct (D)	Beneficial Ownership	
					Code	;	V Ar	mount	or	Pric	ce				(I) (Instr. 4)	(Instr. 4)
Stock		01/03/2020			F ⁽¹⁾		11	19	D	\$ 9.52 (2)	2 1	1,007			D	
Report on a s	separate line fo	Table II -	Derivative Secu	ıritie	es Acqu	P	erson ontain ne forr	ns who ned in m dis	o responding this for plays and the formula of the	orm a a cur	are r rrent	not requ lly valid	ired to res	pond unle	ss	1474 (9-02)
2	2 Transaction		3 / 1 /									e and	8 Price of	0 Number	of 10	11. Natur
	ersion Date ercise (Month/Day/ of attive	Execution Da /Day/Year) any	te, if Transaction Code		Number				A U S	Amount of Underlying Securities			Derivative Securities Beneficially Owned Following Reported	Owners Form of Derivat Securit Direct of or India (s) (I)	hip of Indired Beneficia Ownersh (Instr. 4) D)	
			Code	V ((A) (E	E				ion T	Γitle	or Number of				
	AM, MA (Conversion or Exercise Price of Derivative	enda (First) EGATE PHARMACE 1 WAVERLY OAKS (Street) AM, MA 02452 (State) ecurity Stock Report on a separate line for Exercise Price of Derivative 2. (Month/Day/	d Address of Reporting Person* enda (First) (Middle) EGATE PHARMACEUTICALS, I WAVERLY OAKS ROAD, SUITE (Street) AM, MA 02452 (State) (Zip) ecurity 2. Transaction Date (Month/Day/Year) Table II - Conversion or Exercise Price of Derivative 3. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 3. A. Deemed Execution Date any (Month/Day/Year)	and Address of Reporting Person* enda 2. Issuer Name YEGATE [EYEG] 3. Date of Earl O1/03/2020 3. Date of Earl O1/03/2020 4. If Amendment Am, MA 02452 (Street) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Table II - Derivative Securities beneficially and Execution Date (e.g., puts, calls Price of Derivative Security 3. Date of Earl O1/03/2020 2. Transaction Date (Month/Day/Year) 3. Deemed Execution Date (e.g., puts, calls any (Month/Day/Year) 3. Transaction Date (e.g., puts, calls any (Month/Day/Year) 3. Transaction Date (in the privative Security (Month/Day/Year) 3. Deemed Execution Date (in the privative Security (Month/Day/Year) 4. Transaction Date (In the privative Security (Month/Day/Year) (Month/Day/Year)	and Address of Reporting Person enda 2. Issuer Name are EYEGATE PH. [EYEG] 3. Date of Earliest of 01/03/2020 (Street) 4. If Amendment, If Amendment, If (Month/Day/Year) (Street) AM, MA 02452 (State) (State) (Zip) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Table II - Derivative Securities beneficially ow (Month/Day/Year) 2. Table II - Derivative Securities (e.g., puts, calls, ware are EYEGATE PH. [EYEG] 3. Date of Earliest of 01/03/2020 2. Transaction Date (Month/Day/Year) 3. Date of Earliest of 01/03/2020 2. Transaction Date (Month/Day/Year) 3. Demed Execution Date, if (e.g., puts, calls, ware are EYEGATE PH. [EYEG] 3. Date of Earliest of 01/03/2020 2. Transaction Date (Month/Day/Year) 3. Demed Execution Date, if one Execution Date, if any (Month/Day/Year) 4. If Amendment, II are cution Date, if one Calls of Execution Date, if one Execution	d Address of Reporting Person* enda 2. Issuer Name and Tick EYEGATE PHARM. [EYEG] 3. Date of Earliest Transaction Date (Month/Day/Year) (Street) 4. If Amendment, Date Or AM, MA 02452 2. Transaction Date (Month/Day/Year) (Stock 01/03/2020 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Instr. 3) Code (Instr. 3) Table II - Derivative Securities Acquire (e.g., puts, calls, warrants, acquire (a.g., puts, calls, warrants, acquire (a.g., puts, calls, warrants, acquire (A) or Dispose of (D) (Instr. 3) (Instr. 3) A. Deemed Execution Date (a.g., puts, calls, warrants, acquire (a.g., puts, calls, warrants, acquire (a.g., puts, calls, warrants, acquire (A) or Dispose of (D) (Instr. 3) (Instr. 3)	d Address of Reporting Person enda 2. Issuer Name and Ticker of EYEGATE PHARMACI [EYEG] 3. Date of Earliest Transaction 01/03/2020 4. If Amendment, Date Original Amendm	2. Issuer Name and Ticker or Tradit EYEGATE PHARMACEUTI [EYEG] 3. Date of Earliest Transaction (Month Day/Year) 4. If Amendment, Date Original Filed Execution Date, if (Month/Day/Year) 5. Table II - Derivative Securities Acquired (Month/Day/Year) 7. Table II - Derivative Securities Acquired (Month/Day/Year) 8. Transaction Date (Instr. 8) 9. Table II - Non-Derivative Securities Acquired (Month/Day/Year) 1. Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 1. Date Exercise Pharmaceurity (Month/Day/Year) 1. Stock	and Address of Reporting Person* enda 2. Issuer Name and Ticker or Trading Syr EYEGATE PHARMACEUTICALS [EYEG] 3. Date of Earliest Transaction (Month/Day 01/03/2020 3. Date of Earliest Transaction (Month/Day 01/03/2020 4. If Amendment, Date Original Filed, Month/Day O1/03/2020 4. If Amendment, Date Original Filed, Month/Day/Year O1/03/2020 5. Code V Amount O1/03/2020 6. Stock O1/03/2020 7. Code V Amount O1/03/2020 8. Table II - Derivative Securities Acquired, Disposed of (Execution Date, if O1/03/2020 7. Code V Amount O1/03/2020 8. Table II - Derivative Securities Acquired, Disposed of O1/03/2020 7. Code V Amount O1/03/2020 8. Table II - Derivative Securities Acquired, Disposed of O1/03/2020 9. Code V Amount O1/03/2020 1. Table II - Derivative Securities Acquired, Disposed of O1/03/2020 1. Table II - Derivative Securities Acquired, Disposed of O1/03/2020 1. Table II - Derivative Securities Acquired, Disposed of O1/03/2020 2. Code V Amount O1/03/2020 3. Transaction O1/03/2020 4. Transaction O1/03/2020 6. Date Exercisable O1/03/2020 9. Date O1/03/2020 1. Table II - Derivative Securities Acquired O1/03/2020 1. Table II - Derivative Securities Acquired O1/03/2020 1. Table II - Derivative Securities Acquired O1/03/2020 2. Date Exercisable O1/03/2020 3. Transaction O1/03/2020 9. Date Exercisable O1/03/2020 1. Date O1/03/20	2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG] 3. Date of Earliest Transaction (Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) 5. Transaction Date (Month/Day/Year) 6. Stock 6. Date Execution Date, if (Month/Day/Year) 7. Table II - Derivative Securities Acquired, Disposed of Ord Derivative Security 7. Table II - Derivative Securities Acquired, Disposed of Ord Derivative Security (Month/Day/Year) 8. Transaction Date (Month/Day/Year) 8. Transaction Date (Month/Day/Year) 9. Table II - Derivative Securities Acquired, Disposed of Ord Derivative Security (Month/Day/Year) 1. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Code (Instr. 8) 1. Transaction Date (Month/Day/Year) 1. Transaction Date (Month/Day/Year) 1. Transaction Date (Instr. 8) 2. Date Exercisable Expiration Date (Instr. 3, 4, and 5)	2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG] 3. Date of Earliest Transaction (Month/Day/Year) 4. If Amendment, Date Original Filed(Month/Day/Year) 5. Table I - Non-Derivative Securities Acquired (Instr. 8) 6. Code	and Address of Reporting Person and and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG] Comparison (Middle) Code (Instr. 8) Code (Middle) Code (Instr. 8) Code (Instr	2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG] 3. Date of Earliest Transaction (Month/Day/Year) 5. Relation Direct (EYEG) 6. Individual Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC (EYEG] 7. Office (Instr. 3) 7. Of	2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG] 3. Date of Earliest Transaction (Month/Day/Year) 01/03/2020 4. If Amendment, Date Original Filed(Month/Day/Year) 01/03/2020 4. If Amendment, Date Original Filed(Month/Day/Year) 01/03/2020 5. Relationship of Rep (Che (Che (Type)) 10/03/2020 6. Individual or Joint/C X Form filed by More Rape Filed (Month/Day/Year) 10/03/2020 7. Table 1 - Non-Derivative Securities Acquired (Instr. 8) 10/03/2020 8. Amount of Securities Acquired (Instr. 8) 11/03/2020 8. Amount of Securities Acquired (Instr. 3, 4 and 5) 11/03/2020 8. Amount of Securities Acquired (Instr. 3) 11/03/2020 8. Full 119 D 9.52 11,007 11/03/2020 11/03	2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG] 3. Date of Earliest Transaction (Month/Day/Year) 01/03/2020 4. If Amendment, Date Original Filed(Month/Day/Year) 01/03/2020 5. Relationship of Reporting Person VP of Research & De VP of R	2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYFG] (Size) (Month/Day/Year) (M

Reporting Owners

	Relationships					
Reporting Owner Name / Address		10% Owner	Officer	Other		
Mann Brenda C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLY OAKS ROAD, SUITE 108 WALTHAM, MA 02452			VP of Research & Development			

Signatures

/s/ Sarah Romano, Attorney-in-Fact*	01/06/2020

**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale of shares to cover taxes due on restricted stock that vested on 01/01/2020.
 - The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$9.3537 to \$9.52, inclusive. The reporting
- (2) person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.